Join the Urinary Tract Infection group to help and get support from people like you.
Urinary Tract Infection News (Page 2)
Related terms: Acute Bacterial Cystitis, Catheter-Associated Urinary Tract Infection (UTI), Chronic Urinary Tract Infection (UTI), Cystitis, acute bacterial, Infection, Urinary Tract, UTI, Catheter-Associated Urinary Tract Infection, Chronic Urinary Tract Infection, Urinary Infection
Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients
DUBLIN, March 18, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA)...
Zemdri (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) – Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multidrug...
FDA Approves Vabomere (meropenem and vaborbactam) for Complicated Urinary Tract Infections
August 29, 2017 – The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis,...
FDA Medwatch Alert: Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects
ISSUE: FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). Includes the following currently available fluoroquinolones:...
FDA Medwatch Alert: Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections
ISSUE: FDA is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated...
FDA Medwatch Alert: Zerbaxa (ceftolozane and tazobactam): Drug Safety Communication - FDA Cautions about Dose Confusion and Medication Errors
ISSUE: The U.S. Food and Drug Administration (FDA) is warning health care professionals about the risk for dosing errors with the antibacterial drug Zerbaxa (ceftolozane and tazobactam) due to...
FDA Approves Avycaz (ceftazidime and avibactam) for Complicated Abdominal and Urinary Tract Infections
February 25, 2015 – The U.S. Food and Drug Administration today approved Avycaz (ceftazidime-avibactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections...
FDA Approves Zerbaxa (ceftolozane/tazobactam) for Complicated Intra-Abdominal/Urinary Tract Infections
December 19, 2014 – The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal...
Further information
Related condition support groups
Bladder Infection, Kidney Infections, Infections
Related drug support groups
amoxicillin, doxycycline, Bactrim, Cipro, nitrofurantoin, ciprofloxacin, Macrobid, Augmentin, Levaquin, view more... levofloxacin, trimethoprim, amoxicillin / clavulanate, sulfamethoxazole / trimethoprim, Bactrim DS, cranberry, Rocephin